The aim of this study was to relate the CpG island methylator phenotype (CIMP; characterized by extensive promoter hypermethylation) to cancer-specific survival in colorectal cancer, taking into consideration relevant clinicopathologic factors, such as microsatellite instability (MSI) screening status and the BRAF V600E mutation.
Department of Medical Biosciences, Pathology, and Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden. anna.dahlin@medbio.umu.se